Drug Information
Drug (ID: DG00465) and It's Reported Resistant Information
| Name |
Carboplatin/Paclitaxel
|
||||
|---|---|---|---|---|---|
| Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(1 diseases)
[1]
|
||||
Type(s) of Resistant Mechanism of This Drug
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Carboxylesterase 4A (CES4A) | [1] | |||
| Molecule Alteration | Missense mutation | p.P55S |
||
| Resistant Disease | Ovarian cancer [ICD-11: 2C73.0] | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | AXLK signaling pathway | Activation | hsa01521 | |
| In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
| Experiment for Molecule Alteration |
Circulating-free DNA assay; Whole exome sequencing assay | |||
| Mechanism Description | Quantification of allele fractions in plasma identified increased representation of mutant alleles in association with emergence of therapy resistance. | |||
| Key Molecule: Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1) | [1] | |||
| Molecule Alteration | Missense mutation | p.M889K |
||
| Resistant Disease | Ovarian cancer [ICD-11: 2C73.0] | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | AXLK signaling pathway | Activation | hsa01521 | |
| In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
| Experiment for Molecule Alteration |
Circulating-free DNA assay; Whole exome sequencing assay | |||
| Mechanism Description | Quantification of allele fractions in plasma identified increased representation of mutant alleles in association with emergence of therapy resistance. | |||
References
visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.
